Contact
i.elserafi@ajman.ac.ae
06 705 5345
Ajman Campus
Ibrahim Taher Ibrahim El Serafi

  • Ibrahim Taher Ibrahim El Serafi

  • Associate Professor
  • Ext: 5345
  • CV

I am an Associate Professor in the College of Medicine at Ajman University. I teach Biochemistry and Molecular Medicine courses for Foundation, first and third year students. After my graduation from the Faculty of Medicine, Suez Canal University, Egypt; I started both my clinical and teaching career at the department of Medical Biochemistry and Molecular Biology in 2004. After obtaining my Master degree in molecular biology, I moved to Karolinska Institutet for my PhD in January 2010 and defended my thesis at department of Laboratory Medicine. Later, I was intensively involved in clinical practice and teaching for two years at the Faculty of Medicine, Port-Said University, Egypt as an assistant professor of Biochemistry. I joined later on (2017), as a post-doctoral fellow, Linköping University, Sweden and in 2018, I returned to Karolinska Institutet as a post-doctoral fellow then as an assistant professor at department of Oncology-Pathology. My research experience is placed between the areas of pharmacogenomics, personalized medicine, adoptive T cell therapy and the development of animal models. I also have a vast experience for the development and validation of analytical methods using different analytical techniques.

Education
  • PhD, Department of Laboratory Medicine, Karolinska Institutet, Sweden, 2014
  • Master degree, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Egypt, 2007
  • M.B.B. Ch , Faculty of Medicine, Suez Canal University, Egypt, 2002
Experience
  • Assistant professor at Department of Oncology-Pathology, Karolinska Institutet, Sweden, 2019
  • Post-doctoral fellow, Department of Oncology-Pathology, Karolinska Institutet, Sweden, 2018
  • Post-doctoral fellow, Department of Clinical-Experimental Medicine, Linköping University, Sweden, 2017
  • Assistant professor, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Port-Said University, Egypt, 2015
  • Post-doctoral fellow, Department of Laboratory Medicine, Karolinska Institutet, Sweden, 2014
  • PhD student, Department of Laboratory Medicine, Karolinska Institutet, Sweden, 2010
  • Assistant lecturer at Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Egypt, 2008
  • Demonstrator at Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Egypt, 2004
Teaching Area
  • Molecular Medicine
  • General Chemistry
  • Basic Biochemistry
  • Clinical Biochemistry
Research
  • Adoptive T cell therapy
  • Personalized medicine
  • Pharmacogenomics
  • Hematopoietic stem cell transplantation
  • Hematological disorders
  • Animal models
Publications
Conference Presentation
  • Characterization of MSLN CAR T-cells in an ovarian cancer model; poster presentation at Frontiers in Cancer Research and Therapy. 2018, March 8-9, Stockholm, Sweden.
  • Vitamin D Relation to Busulphan in Pediatrics Undergoing Hematopoietic Stem Cell Transplantation; abstract at The American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017, December 9-12, Atlanta, GA, USA.
  • Biodistribution of busulphan metabolites and their effect on central nervous system; poster presentation at the 23rd Mayo Clinic-Karolinska Institutet Annual Scientific Research Meeting. 2017, September 7-8, Stockholm, Sweden.
  • Toxicological side-effects of Fludarabin and Treosulfan conditioning before allogeneic stem-cell transplantation; poster presentation at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). 2017, March 26-29, Marseille, France.
  • Towards personalized medicine on pharmacogenomics basis; oral presentation at the 1st annual conference of the Faculty of Medicine, Port-Said University. 2016, March 24-25, Port-Said, Egypt.
  • The importance of pharmacogenomics in personalized conditioning regimen prior to stem cell transplantation; oral presentation at the 1st annual biomedical conference, Recent advances in stem cell research, Faculty of Medicine, Suez Canal University. 2015, October 29-30, Ismailia, Egypt.
  • Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs; poster presentation at the 56th American Society of Hematology (ASH) annual Meeting and exposition. December 6-9 2014, San Francisco, CA, USA.
  • The role of CYP2J2 in cyclophosphamide metabolism; poster presentation at the 18th congress of the European Hematology Association (EHA). 2013, June 13 16, Stockholm, Sweden.
  • Microbubbles and microcapsules as drug delivery vehicles for chemotherapy; poster presentation at Label-Free Technologies Conference, Advances and Applications. 2012, November 1-3, Amsterdam, Netherlands.
  • The role of human CYP2B6 polymorphism and reductase on bioactivation of cyclophosphamide; invited speaker at the 17th congress of the European Hematology Association (EHA). 2012, June 14-18, Amsterdam, Netherlands.
  • Molecular analysis of the possible mutations in the gamma globin gene in patients with beta thalassemia in Suez Canal Region; oral presentation at the 5th Scientific Congress of Clinical Pathology Department, Faculty of Medicine, Suez Canal University. 2007, May, Ismailia, Egypt.
  • Tumor tailored lymphodepletion and CAR T-cell functionality in advanced ovarian cancer; poster presentation at 2nd Translational Research Conference Immune & Cellular Therapies: Focus on Advanced Gene-Engineered Immune Cells”, organized by The European School of Hematology (ESH). 2022, September 12-14, Berlin, Germany
  • Mesothelin Directed Chimeric Antigen Receptor T Cell Therapy for Treatment of Advanced Ovarian Cancer; poster presentation at The International Conference Immune and Cellular Therapies: Focus on Immune Based Therapeutic Concepts”, organized by The European School of Hematology (ESH). 2019, September 20-22, Mandelieu, France.
  • Immunotherapy for cancer treatment; plenary speaker at Recent Advances in Molecular and Cellular Medicine, the Center of Excellence in Molecular and Cellular Medicine second annual conference, Faculty of Medicine, Suez Canal University. 2018, December 26-27, Ismailia, Egypt.
  • The Establishment of Ovarian Cancer Mouse Model for The Evaluation of MSLN CAR T-cells; oral presentation at Kick-Off 2018, Oncology-Pathology department, Karolinska Institutet. 2018, August 29th, Stockholm, Sweden.
  • Reduced risk of sinusoidal obstruction syndrome of the liver after Bu-Cy conditioning before allogeneic hematopoietic stem cell transplantation, a result of personalized dose adjustment; abstract at the 23rd congress of the European Hematology Association (EHA). 2018, June 14-17, Stockholm, Sweden.
  • Pre-analytical investigations for establishing a protocol for treosulfan handling and activation; abstract at the 23rd congress of the European Hematology Association (EHA). 2018, June 14-17, Stockholm, Sweden.
  • The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation; oral presentation at The International Hematologists Summit. 2018, May 21-22, Valencia, Spain.
Memberships, Awards and Honors
  • Declaration of Honor from the Center of Excellence in Molecular and Cellular Medicine, Faculty of Medicine, Suez Canal University, Egypt, 2018
  • European Hematology Association (EHA), 2012
  • Swedish Medical Association (SLS), 2017